North Chicago – October 19, 2026 -- AbbVie's investigational dual-targeting therapy ABBV-466 delivered endoscopic remission in 40.5% of Crohn's disease patients at Week 24, against 22.4% for risankizumab and 20.0% for trosunilimab monotherapy, according to Phase 2a TARGET-CD data (NYSE: ABBV).

Shanghai – October 18, 2026 -- Mabwell's Nectin-4-targeting antibody-drug conjugate 9MW2821 (Bulumtatug Fuvedotin, "BFv") achieved a 30.0% objective response rate in 60 efficacy-evaluable triple-negative breast cancer (TNBC) patients previously treated with a topoisomerase I (Topo I) ADC, according to Phase II data to be presented orally at the 2026 European Society for Medical Oncology (ESMO) Congress.

Seoul – October 18, 2026 -- XellSmart's off-the-shelf Parkinson's cell therapy XS411 improved OFF-state motor scores by an average of more than 30 points at six months in all nine Phase I participants, and its 30-patient Phase II trial in China has completed enrollment.

The data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). The company says the results showed no dose-limiting toxicities, serious adverse events or adverse events related to XS411.

Indianapolis – October 15, 2026 -- More than one in four ulcerative colitis (UC) patients (27.7%) treated with Eli Lilly and Company's Omvoh (mirikizumab-mrkz) achieved comprehensive disease control at one year, compared with 14% on placebo, according to a post hoc analysis of the LUCENT-2 trial.

In the VIVID-1 Crohn's disease trial, 20.4% of Omvoh-treated patients reached corticosteroid-free deep remission, versus 2% on placebo. Lilly will present both analyses at United European Gastroenterology (UEG) Week 2026.

Washington – October 14, 2026 -- Vanda Pharmaceuticals (Nasdaq: VNDA) has put its VQW-765 program on hold after the Phase III Study 3201 in adults with social anxiety disorder missed its primary endpoint, and the company said the data did not confirm earlier Phase II findings.

Uppsala – October 13, 2026 -- Akiram Therapeutics reported no dose-limiting toxicities among the eight patients treated so far with its lead radiopharmaceutical candidate 177Lu-AKIR001 in a Phase I trial, with treatment-related adverse events limited to grade 1-2.

The Swedish clinical-stage biotech will present the first clinical data at the EANM 2026 Congress in Vienna, October 17-21. The abstract was selected as a Top Rated Oral Presentation (TROP).

Burlington – October 12, 2026 -- Eighty-six percent of 21 heart failure patients at imminent risk of hospital admission were decongested at home without hospitalization using SQ Innovation's subcutaneous furosemide product Lasix ONYU, according to interim results from the investigator-sponsored Gator SCALES-WHF study.

Three patients were admitted within 30 days for additional treatment. The data were presented on October 11 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, Arizona.

Seoul – October 12, 2026 -- Parkinson's patients taking the investigational drug solengepras gained an average of 36 more minutes of "good" movement time per day than those on their regular medication alone, and the drug will now be submitted to the U.S. Food and Drug Administration for approval.

San Carlos – October 12, 2026 -- Noah Medical's Galaxy System robotic bronchoscopy platform achieved 100% tool-in-lesion accuracy and 100% successful navigation to small peripheral lesions in its first-in-human FRONTIER Study, according to final results published in the Official Journal of the Asian Pacific Society of Respirology.

Toronto – October 12, 2026 -- Men treated with whole-gland TULSA Procedure showed no median change in penile length at one month, compared with a median 0.65 cm reduction after robotic radical prostatectomy (RP), according to new data from the Level 1 CAPTAIN randomized controlled trial, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced.